Bicycle Therapeutics Plc (BCYC)
4.30
+0.06
(+1.42%)
USD |
NASDAQ |
Sep 04, 16:00
4.295
0.00 (0.00%)
After-Hours: 20:00
Bicycle Therapeutics Research and Development Expense (Quarterly) : 47.76M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 47.76M |
| March 31, 2026 | 54.84M |
| December 31, 2025 | 58.15M |
| September 30, 2025 | 65.63M |
| June 30, 2025 | 83.58M |
| March 31, 2025 | 68.63M |
| December 31, 2024 | 61.22M |
| September 30, 2024 | 57.39M |
| June 30, 2024 | 47.42M |
| March 31, 2024 | 50.18M |
| December 31, 2023 | 51.14M |
| September 30, 2023 | 44.87M |
| June 30, 2023 | 45.89M |
| March 31, 2023 | 39.74M |
| December 31, 2022 | 32.33M |
| September 30, 2022 | 28.96M |
| June 30, 2022 | 24.51M |
| March 31, 2022 | 14.60M |
| Date | Value |
|---|---|
| December 31, 2021 | 12.97M |
| September 30, 2021 | 11.46M |
| June 30, 2021 | 12.50M |
| March 31, 2021 | 9.727M |
| December 31, 2020 | 10.55M |
| September 30, 2020 | 7.597M |
| June 30, 2020 | 7.978M |
| March 31, 2020 | 7.779M |
| December 31, 2019 | 6.739M |
| September 30, 2019 | 6.040M |
| June 30, 2019 | 6.505M |
| March 31, 2019 | 6.343M |
| December 31, 2018 | 6.544M |
| September 30, 2018 | 5.651M |
| June 30, 2018 | 4.856M |
| March 31, 2018 | 3.734M |
| December 31, 2017 | 4.542M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Autolus Therapeutics Plc | 27.95M |
| Biodexa Pharmaceuticals Plc | -- |
| Akari Therapeutics Plc | 2.081M |
| DBV Technologies SA | 28.96M |
| Cellectis SA | 20.89M |